GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotechnology Assets SA (XMAD:BST) » Definitions » Gross-Profit-to-Asset %

Biotechnology Assets (XMAD:BST) Gross-Profit-to-Asset % : 23.71% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Biotechnology Assets Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Biotechnology Assets's annualized Gross Profit for the quarter that ended in Dec. 2023 was €4.02 Mil. Biotechnology Assets's average Total Assets over the quarter that ended in Dec. 2023 was €16.96 Mil. Therefore, Biotechnology Assets's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 23.71%.


Biotechnology Assets Gross-Profit-to-Asset % Historical Data

The historical data trend for Biotechnology Assets's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotechnology Assets Gross-Profit-to-Asset % Chart

Biotechnology Assets Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.40 4.82 15.15 13.74 19.92

Biotechnology Assets Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.37 9.82 17.72 16.59 23.71

Competitive Comparison of Biotechnology Assets's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Biotechnology Assets's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotechnology Assets's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Biotechnology Assets's Gross-Profit-to-Asset % falls into.



Biotechnology Assets Gross-Profit-to-Asset % Calculation

Biotechnology Assets's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=3.494/( (18.475+16.607)/ 2 )
=3.494/17.541
=19.92 %

Biotechnology Assets's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=4.02/( (17.303+16.607)/ 2 )
=4.02/16.955
=23.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Biotechnology Assets Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Biotechnology Assets's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotechnology Assets (XMAD:BST) Business Description

Traded in Other Exchanges
N/A
Address
Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.